Oral Abstract Session:
199. Clinical Trials that May Change Your Practice
Saturday, October 6, 2018: 8:45 AM-10:00 AM
Room: S 158

Tracks: Pediatric ID, Investigative ID, Adult ID, Trainee

Moderators:  David Van Duin, MD, PhD, University of North Carolina at Chapel Hill and Helen W. Boucher, MD, FIDSA, Tufts Medical Center

8:45 AM
A randomized, double-blind, placebo-controlled multicenter phase 2 trial to examine the effects of DAS181 in immunocompromised (IC) patients with parainfluenza virus (PIV) lower respiratory tract infection (LRTI) on supplemental oxygen (SO)
Roy F. Chemaly, MD, MPH, FIDSA, FACP; Ronald Moss, MD; Francisco M Marty, MD; Cameron R. Wolfe, MBBS (Hons), MPH, FIDSA; Steven J. Lawrence, M.D., M.Sc.; Sanjeet Dadwal, MD; Rosemary Soave, MD, FIDSA; Jimmy Hwang, PhD; Stephen Hawley, PhD; Rebecca Routh, PhD; Jennifer Ho, PhD; George Wang, SCD; Nancy Chang, PhD; Michael Boeckh, MD, PhD, FIDSA
9:00 AM
Results of the Respiratory Protection Effectiveness Clinical Trial (ResPECT)
Lewis Radonovich, MD; Michael S. Simberkoff, MD, FIDSA; Mary Bessesen, MD; Alexandria C Brown, PhD; Derek Cummings, PhD; Charlotte Gaydos, DrPH, FIDSA; Jenna Los, MLA; Amanda Krosche, BS; Cynthia Gibert, MD, MSc, FIDSA; Geoffrey Gorse, MD, FIDSA; Ann-Christine Nyquist, MD, MSPH, FPIDS; Nicholas Reich, PhD; Maria Rodriguez-Barradas, MD, FIDSA; Connie Price, MD; Trish Perl, MD, MSc, FIDSA, FSHEA
9:30 AM
Rezafungin Clinical Safety and Efficacy in Patients with Candidemia and/or Invasive Candidiasis in the Randomized, Double-blind, Multicenter, Phase 2 STRIVE Study
George R Thompson, MD; Jose Vazquez, MD, FACP, FIDSA; Alex Soriano, MD, PhD; Athanasios Skoutelis, MD; Luis Ostrosky-Zeichner, MD, FIDSA, FSHEA; Karen Mena, BA; Laura Navalta, BA; Taylor Sandison, MD, MPH; Peter Pappas, MD
9:45 AM
Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
John Bradley, MD, FAAP; Antonio Arrieta, MD, FIDSA; Paula Bokesch, MD, FAAP; Karen Fusaro, BA; David C Griffith, BA; Jeffrey S. Loutit, MBChB

CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.